AU2005229411B2 - Polypeptide sequence involved in the modulation of the immunosuppressive effect of viral proteins - Google Patents

Polypeptide sequence involved in the modulation of the immunosuppressive effect of viral proteins Download PDF

Info

Publication number
AU2005229411B2
AU2005229411B2 AU2005229411A AU2005229411A AU2005229411B2 AU 2005229411 B2 AU2005229411 B2 AU 2005229411B2 AU 2005229411 A AU2005229411 A AU 2005229411A AU 2005229411 A AU2005229411 A AU 2005229411A AU 2005229411 B2 AU2005229411 B2 AU 2005229411B2
Authority
AU
Australia
Prior art keywords
protein
seq
env
mutated
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005229411A
Other languages
English (en)
Other versions
AU2005229411A1 (en
Inventor
Thierry Heidmann
Marianne Mangeney
Martial Renard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Gustave Roussy (IGR)
Universite Paris Saclay
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Gustave Roussy (IGR)
Universite Paris Saclay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Gustave Roussy (IGR), Universite Paris Saclay filed Critical Centre National de la Recherche Scientifique CNRS
Publication of AU2005229411A1 publication Critical patent/AU2005229411A1/en
Application granted granted Critical
Publication of AU2005229411B2 publication Critical patent/AU2005229411B2/en
Assigned to Universite Paris-Saclay, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT GUSTAVE ROUSSY reassignment Universite Paris-Saclay Request for Assignment Assignors: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT GUSTAVE ROUSSY, UNIVERSITE PARIS SUD XI
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2005229411A 2004-03-30 2005-03-30 Polypeptide sequence involved in the modulation of the immunosuppressive effect of viral proteins Ceased AU2005229411B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04290838.4 2004-03-30
EP04290838 2004-03-30
PCT/EP2005/003339 WO2005095442A1 (en) 2004-03-30 2005-03-30 Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins

Publications (2)

Publication Number Publication Date
AU2005229411A1 AU2005229411A1 (en) 2005-10-13
AU2005229411B2 true AU2005229411B2 (en) 2010-11-18

Family

ID=34896141

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005229411A Ceased AU2005229411B2 (en) 2004-03-30 2005-03-30 Polypeptide sequence involved in the modulation of the immunosuppressive effect of viral proteins

Country Status (14)

Country Link
US (2) US8178657B2 (enExample)
EP (1) EP1732585B1 (enExample)
JP (1) JP5060284B2 (enExample)
CN (1) CN1961001B (enExample)
AT (1) ATE472334T1 (enExample)
AU (1) AU2005229411B2 (enExample)
BR (1) BRPI0509497B1 (enExample)
CA (1) CA2561376C (enExample)
DE (1) DE602005022056D1 (enExample)
ES (1) ES2347445T3 (enExample)
IL (1) IL178205A (enExample)
MX (1) MXPA06011272A (enExample)
WO (1) WO2005095442A1 (enExample)
ZA (1) ZA200608178B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9777044B2 (en) 2003-05-02 2017-10-03 Centre National De La Recherche Scientifique (Cnrs) GLUT-1 as a receptor for HTLV envelopes and its uses
ATE538802T1 (de) 2005-03-30 2012-01-15 Viroxis Endogener retrovirus und proteine, kodiert durch env-gen, als target für die krebsbehandlung
US20070185025A1 (en) * 2005-09-11 2007-08-09 The Trustees Of Columbia University In The City Of New York Filoviral immunosuppressive peptides and uses thereof
US20080299150A1 (en) * 2007-05-08 2008-12-04 Sankhia Corporation Method and system for processing immuno-competent cells in view of an antiviral therapy, and related therapeutic process
US8323891B2 (en) * 2008-08-01 2012-12-04 Claflin University miRNA triplex formations for the downregulation of viral replication
RU2008140688A (ru) * 2008-10-15 2010-04-20 Михаил Аркадьевич Шурдов (RU) Иммуносупрессивный пептид
JP5624994B2 (ja) 2009-01-09 2014-11-12 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク 新たなレセプター結合性リガンド、生物学的対象の細胞の検出におけるその使用
WO2011092199A1 (en) * 2010-01-26 2011-08-04 Institut Gustave Roussy Mutated xmrv env proteins in the immunosuppressive domain
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
WO2012035369A1 (en) * 2010-09-17 2012-03-22 Centre National De La Recherche Scientifique Method for the diagnosis and/or prognosis of inflammatory states
BR112014001287B1 (pt) * 2011-07-20 2020-12-08 Centre National De La Recherche Scientifique vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina
US9636396B2 (en) 2011-12-07 2017-05-02 Centre National De La Recherche Scientifique Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties
CA2856180C (en) 2011-12-07 2022-09-06 Viroxis S.A.S. Mutated lentiviral env proteins and their use as drugs
WO2014195510A1 (en) * 2013-06-07 2014-12-11 Viroxis S.A.S. Mutated non-primate lentiviral env proteins and their use as drugs
EP3309178A4 (en) * 2015-06-11 2019-05-08 Keio University FUSION PROTEIN OR CONJUGATED PROTEIN, CARRIER FOR INTRA-CELLULAR DELIVERY, PARTICLE PEPTIDE, CELL MEMBRANE PERMEATION AMPLIFIER, DNA AND VECTOR
CN108368155A (zh) * 2015-10-01 2018-08-03 爱姆维恩公司 人源性免疫抑制蛋白和肽作为药物的应用
WO2019043127A1 (en) 2017-09-01 2019-03-07 Inprother Aps VACCINE FOR USE IN PROPHYLAXIS AND / OR TREATMENT OF DISEASE
US20210403907A1 (en) 2018-09-18 2021-12-30 Vnv Newco Inc. Arc-based capsids and uses thereof
EP3852813A4 (en) 2018-09-18 2022-06-22 VNV Newco Inc. ARC-BASED CAPSIDS AND THEIR USES
US11129892B1 (en) 2020-05-18 2021-09-28 Vnv Newco Inc. Vaccine compositions comprising endogenous Gag polypeptides
EP4277704A1 (en) * 2021-01-13 2023-11-22 Viroxis Measles-hiv or measles-htlv vaccine
CN121752289A (zh) 2023-04-21 2026-03-27 盈珀治疗有限公司 表面展示抗原的改善表达

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4822606A (en) 1986-04-07 1989-04-18 Duke University Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
DE68929419T2 (de) 1988-12-13 2003-04-03 Colorado State University Research Foundation, Fort Collins Prototypische FeLV-Isolate für die Verwendung als Krankheitsmuster oder Impfstoff
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
FR2780069B1 (fr) * 1998-06-23 2002-06-28 Inst Nat Sante Rech Med Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
JP2003512844A (ja) * 1999-10-28 2003-04-08 ユニヴェルシテ・ドゥ・ジュネーブ 多発性硬化症関連スーパー抗原
AU2002230758A1 (en) * 2000-12-11 2002-06-24 Tufts University Treatment and prevention of EBV infection and EBV-associated disorders
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition

Also Published As

Publication number Publication date
US20080008683A1 (en) 2008-01-10
ES2347445T3 (es) 2010-10-29
JP2008506357A (ja) 2008-03-06
ZA200608178B (en) 2008-10-29
EP1732585B1 (en) 2010-06-30
EP1732585A1 (en) 2006-12-20
WO2005095442A8 (en) 2006-11-02
US20120189647A1 (en) 2012-07-26
BRPI0509497A (pt) 2007-09-11
ATE472334T1 (de) 2010-07-15
CA2561376C (en) 2016-06-21
US8178657B2 (en) 2012-05-15
BRPI0509497B1 (pt) 2022-07-19
MXPA06011272A (es) 2007-04-17
AU2005229411A1 (en) 2005-10-13
WO2005095442A1 (en) 2005-10-13
JP5060284B2 (ja) 2012-10-31
CN1961001B (zh) 2012-09-05
IL178205A0 (en) 2006-12-31
US8597657B2 (en) 2013-12-03
CN1961001A (zh) 2007-05-09
CA2561376A1 (en) 2005-10-13
DE602005022056D1 (de) 2010-08-12
IL178205A (en) 2015-05-31

Similar Documents

Publication Publication Date Title
US8597657B2 (en) Mutated env sequence involved in the modulation of the immunosuppressive effect of viral proteins
US10335482B2 (en) Method of inducing an anti-HIV-1 immune response comprising administering a C5/TM-GP41 peptide dimer
PT1035865E (pt) Tat do hiv-1 ou respectivos derivados para vacinação profiláctica e terapêutica
JP6612237B2 (ja) ヒトｔリンパ向性ウイルス１型に対する免疫応答を生成するためのレンチウイルスベクター
KR20230112691A (ko) 바이러스 감염을 치료하기 위한 방법 및 조성물
WO2011092199A1 (en) Mutated xmrv env proteins in the immunosuppressive domain
US10143737B2 (en) Method for the vaccination against HIV
JP2018150370A (ja) レンチウイルスの変異ｅｎｖタンパク質及び薬物としてのその使用
US20220184202A1 (en) A recombinant htlv-1 vaccine

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: INSTITUT GUSTAVE ROUSSY

Free format text: FORMER OWNER(S): UNIVERSITE PARIS SUD XI; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; INSTITUT GUSTAVE ROUSSY

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Free format text: FORMER OWNER(S): UNIVERSITE PARIS SUD XI; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; INSTITUT GUSTAVE ROUSSY

Owner name: UNIVERSITE PARIS-SACLAY

Free format text: FORMER OWNER(S): UNIVERSITE PARIS SUD XI; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; INSTITUT GUSTAVE ROUSSY

MK14 Patent ceased section 143(a) (annual fees not paid) or expired